Literature DB >> 23198718

ACAT inhibitors: the search for novel cholesterol lowering agents.

Palash Pal1, Hardik Gandhi, Rajani Giridhar, Mange Ram Yadav.   

Abstract

Increased level of serum cholesterol (hyperlipidemia) is the most significant risk factor for the development of atherosclerosis. Cholesterol levels are affected by factors such as rate of endogenous cholesterol synthesis, biliary cholesterol excretion and dietary cholesterol absorption. Acyl CoA: Cholesterol O-acyl transferases (ACAT) are a small family of enzymes that catalyze cholesterol esterification and cholesterol absorption in intestinal mucosal cells and maintain the cholesterol homeostasis in the blood. Inhibition of the ACAT enzymes is one of the attractive targets to treat hyperlipidemia. Literature survey shows that structurally diverse compounds possess ACAT inhibitory properties. In this review, a comprehensive presentation of the literature on diverse ACAT inhibitors has been given.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23198718     DOI: 10.2174/1389557511313080007

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  9 in total

1.  Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.

Authors:  Wei Yang; Yibing Bai; Ying Xiong; Jin Zhang; Shuokai Chen; Xiaojun Zheng; Xiangbo Meng; Lunyi Li; Jing Wang; Chenguang Xu; Chengsong Yan; Lijuan Wang; Catharine C Y Chang; Ta-Yuan Chang; Ti Zhang; Penghui Zhou; Bao-Liang Song; Wanli Liu; Shao-cong Sun; Xiaolong Liu; Bo-liang Li; Chenqi Xu
Journal:  Nature       Date:  2016-03-16       Impact factor: 49.962

Review 2.  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Authors:  Hsin-Pei Shih; Xiaodan Zhang; Alex M Aronov
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

Review 3.  Traditional Chinese medicine for lipid metabolism disorders.

Authors:  Yiping Li; Xiaolong Wang; Zhijie Shen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

Review 4.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

5.  Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis.

Authors:  Meiling Ren; Huanji Xu; Hongwei Xia; Qiulin Tang; Feng Bi
Journal:  Cell Death Discov       Date:  2021-05-29

6.  Effect of inhibiting ACAT-1 expression on the growth and metastasis of Lewis lung carcinoma.

Authors:  Minghong Bi; Xuxu Qiao; Haoran Zhang; Huazhang Wu; Zhenyuan Gao; Hairong Zhou; Mohan Shi; Yaping Wang; Jingru Yang; Jianguo Hu; Weichen Liang; Yonghong Liu; Xujie Qiao; Shanshan Zhang; Zhibiao Zhao
Journal:  Oncol Lett       Date:  2019-05-31       Impact factor: 2.967

7.  Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator.

Authors:  Jing Pan; Qi Zhang; Katie Palen; Li Wang; Lifen Qiao; Bryon Johnson; Shizuko Sei; Robert H Shoemaker; Ronald A Lubet; Yian Wang; Ming You
Journal:  EBioMedicine       Date:  2019-10-31       Impact factor: 8.143

8.  Avasimibe Alleviates Disruption of the Airway Epithelial Barrier by Suppressing the Wnt/β-Catenin Signaling Pathway.

Authors:  Zicong Zhou; Shixiu Liang; Zili Zhou; Jieyi Liu; Xiaojing Meng; Fei Zou; Changhui Yu; Shaoxi Cai
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

9.  LDL Promotes Disorders in β-Cell Cholesterol Metabolism, Implications on Insulin Cellular Communication Mediated by EVs.

Authors:  Lizbeth Guevara-Olaya; Brenda Chimal-Vega; César Yahel Castañeda-Sánchez; Leslie Y López-Cossio; Angel Pulido-Capiz; Octavio Galindo-Hernández; Raúl Díaz-Molina; Josefina Ruiz Esparza-Cisneros; Victor García-González
Journal:  Metabolites       Date:  2022-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.